In this trial of 4038 diabetic patients with chronic kidney disease (not on dialysis) and anemia, patients were randomized to darbepoetin or placebo for a Hb goal of 13 g/dL (with rescue darbepoetin if Hb fell to 9 g/dL in the placebo group). There was no difference between the groups in the primary endpoints (death / cardiovascular event, or death / end stage renal disease), but the darbepoetin group had a higher rate of stroke (hazard ratio 1.92, CI 1.38-2.68). Risks of darbepoetin outweigh the benefits in this patient population (abstract)
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.